Search results
Showing 1 to 15 of 16 results for primary hyperparathyroidism
Hyperparathyroidism (primary): diagnosis, assessment and initial management (NG132)
This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
Awaiting development Reference number: GID-QS10089 Expected publication date: TBC
What are the optimal management strategies for primary hyperparathyroidism during pregnancy?
Question What are the optimal management strategies for primary hyperparathyroidism during pregnancy? Any explanatory notes(if...
utility of bone turnover markers in the diagnosis and management of primary hyperparathyroidism? Any explanatory notes(if applicable)...
Minimally invasive video‑assisted parathyroidectomy (HTG350)
Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.
the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective? Any...
Etelcalcetide for treating secondary hyperparathyroidism (TA448)
Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.
cost-effective management strategy for people whose first surgery for primary hyperparathyroidism is not successful? Any explanatory...
Thoracoscopic excision of mediastinal parathyroid tumours (HTG159)
Evidence-based recommendations on thoracoscopic excision of mediastinal parathyroid tumours. This involves operating on the tumour using a flexible camera inserted through small cuts in the chest (keyhole surgery).
View recommendations for HTG159Show all sections
Sections for HTG159
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Renal and ureteric stones: assessment and management (NG118)
This guideline covers assessing and managing renal and ureteric stones. It aims to improve the detection, clearance and prevention of stones, so reducing pain and anxiety, and improving quality of life.
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.